This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Live Chat

BOSTON ( TheStreet) -- Welcome to June's Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next 90 minutes or so to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

The American Society of Clinical Oncology (ASCO) annual meeting that just ended raised some controversies and issues surrounding Exelixis (EXEL - Get Report), YM BioSciences (YMI) and Neoprobe (NEOP), so let's discuss.

If you're interested in FDA drug approval decisions, we can hash out the looming catalysts for Fibrocell Sciences (FCSC.OB), Transcept Pharmaceuticals (TSPT), NuPathe (PATH) or Seattle Genetics (SGEN - Get Report).

What's the real story behind Titan Pharmaceuticals' (TTNP.OB) surprise announcement this morning disclosing an FDA meeting to change the statistical plan for the ongoing phase III study of Probuphine?

Ask me questions about the large-cap biotech stocks: Biogen Idec (BIIB), Celgene (CELG), Amgen (AMGN) and Gilead Sciences (GILD).

Has anyone figured out why Spectrum Pharmaceuticals (SPPI - Get Report) wants to buy back its stock? Why is Allos Therapeutics (ALTH) trading below $2 a share? Will Cell Therapeutics (CTIC) ever get a new drug approved? Is there any reason to be optimistic about stem cell stocks like Aastrom Biosciences (ASTM), Cytori Therapeutics (CYTX) or Geron (GERN)?

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ASTM $3.61 -2.43%
EXEL $2.60 1.17%
SPPI $5.91 -2.64%
SGEN $35.05 -0.85%
AAPL $124.25 -0.14%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs